Document:

<PAGE>

                                                                  Exhibit 10.4.2

                         [Merck & Co., Inc. Letterhead]

October 24, 1996

Mr. Murray Goldberg
Regeneron Pharmaceutical, Inc.
777 Old Saw Mill River road
Tarrytown, NY  10591

Dear Mr. Goldberg:

This shall serve as a memorandum of our agreement to amend Schedule A of the
Manufacturing Agreement between Merck & Co., Inc. ("Merck") and Regeneron
Pharmaceuticals, Inc. (Regeneron") dated September 18, 1995, so as to permit
Merck to use Room [***], as depicted on the diagram annexed to Schedule A of the
Manufacturing Agreement, in conjunction with Regeneron, for [***] purposes
in support of the manufacture of Product pursuant to said agreement. Room [***]
is indicated in red outline on the diagram attached hereto. Regeneron shall
designate said area as a "[***] area" on the diagram attached to Schedule A of
the Agreement.

In consideration for the [***] use of Room [***] for the term of the Agreement,
Merck, within 60 days of the execution of this letter agreement by Regeneron ,
shall remit to Regeneron a one-time payment of [***].

If the foregoing is agreeable, would you please so indicate by signing, dating
and returning to us the enclosed copy of this letter.

                                                 Very truly yours,

                                                 Merck & Co., Inc.

                                                 /s/John M. Pashko
                                                 -------------------------------
                                                 John M. Pashko
                                                 Date: 11/25/96

The foregoing is agreed to:

Regeneron  Pharmaceuticals, Inc.

/s/Murray Goldberg
------------------
Murray Goldberg
Date: 11/06/96<PAGE>

                                                                  Exhibit 10.4.3

                     AMENDMENT NO. 3 TO THE MERCK-REGENERON
                                    AGREEMENT

WHEREAS, Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. entered into a
Manufacturing Agreement for the INTERMEDIATE, as defined therein, effective as
of September 18, 1995 (the "MANUFACTURING AGREEMENT"); and

WHEREAS, the parties amended the MANUFACTURING AGREEMENT by Letter Agreements
dated September 18, 1995 and October 24, 1996; and

WHEREAS, the parties wish to further amend the MANUFACTURING AGREEMENT.

NOW, THEREFORE, the parties to the MANUFACTURING AGREEMENT do hereby agree as
follows in this Amendment No. 3, entered into as of the 9th of December, 1999:

1.    Section 1.7 of the MANUFACTURING AGREEMENT shall be amended by replacing
      Section 1.7 in its entirety with the following text which shall be
      incorporated into the MANUFACTURING AGREEMENT:

      "1.7  The term "CONSISTENCY AND VALIDATION PERIOD" shall mean that period
            of time commencing with the date of initial MANUFACTURE OF
            INTERMEDIATE in the FACILITY and terminating with the commencement
            of the first CONTRACT YEAR on November 1, 1999."

2.    Section 1.8 of the MANUFACTURING AGREEMENT shall be amended by replacing
      Section 1.8 in its entirety with the following text which shall be
      incorporated into the MANUFACTURING AGREEMENT:

      "1.8  The term "CONTRACT YEAR" shall mean the period of twelve (12)
            consecutive calendar months commencing on the 1st day of November,
            1999 and ending on the 31st day of October, 2000 and each five (5)
            consecutive twelve (12) month periods from November 1 through
            October 31 thereafter such that the second CONTRACT YEAR shall be
            the period from November 1, 2000 through October 31,

<PAGE>

            2001, the third CONTRACT YEAR shall be the period from November 1,
            2001 through October 31, 2002, the fourth CONTRACT YEAR shall be the
            period from November 1, 2002 through October 31, 2003, the fifth
            CONTRACT YEAR shall be the period from November 1, 2003 through
            October 31, 2004 and the sixth CONTRACT YEAR shall be the period
            from November 1, 2004 through October 31, 2005.

3.    Section 13.2 (ii) shall be amended by replacing Section 13.2(ii) in its
      entirety with the following text which shall be incorporated into the
      MANUFACTURING AGREEMENT:

      "13.2(ii) A fee for each BATCH (the "BATCH FEE") of INTERMEDIATE RELEASED
                hereunder, as follows:

<TABLE>
<CAPTION>
Number of            CONTRACT         CONTRACT      CONTRACT
BATCHES               YEAR 1         YEARS 2-4      YEARS 5-6
-------             ----------       ---------      ---------
<S>                  <C>             <C>            <C>
BATCHES [****]      [********]       [*******]      [********]
BATCHES [****]      [********]       [*******]      [********]
BATHCES [****]      [********]       [*******]      [********]
BATCH [**] and Over [********]       [*******]      [********]
</TABLE>

      No fee shall be due under this Section 13.2(ii) regarding any BATCH which
      is not RELEASED."

4.    Section 13.2 shall be amended by adding the following text as Subsection
      (iii) which shall be incorporated into the MANUFACTURING AGREEMENT:

      "13.2(iii) No BATCH FEES or any other compensation will be paid by MERCK
                 to REGENERON for any BATCH listed in Schedule X. However, if
                 following November 1, 1999 MERCK requests REGENERON to perform
                 any rework of any BATCH listed in Schedule X, the parties will
                 agree in writing on the compensation to be paid to REGENERON
                 for the rework before it is performed."

      A copy of Schedule X is attached hereto and incorporated into the
      MANUFACTURING AGREEMENT.

5.    Section 3 of Schedule H shall be amended by replacing Section 3 in its
      entirety with the following text which shall be incorporated into the
      MANUFACTURING AGREEMENT:

                                       2
<PAGE>

      "3.   SHORTFALL FEE

            If at the end of any CONTRACT YEAR, there are any SHORTFALL BATCHES,
            MERCK shall pay to REGENERON an amount ("the SHORTFALL FEE") equal
            To the number of SHORTFALL BATCHES in the CONTRACT YEAR multiplied
            by the sum of the STANDARD LABOR COST plus the BATCH FEE for that
            CONTRACT YEAR plus any costs, the amount of which the parties will
            agree to in writing on a case-by-case basis, for electricity, waste
            hauling, supplies and water for injection which are directly related
            to the fact that there are SHORTFALL BATCHES."

6.    REGENERON has submitted invoices to MERCK dated December 29, 1998 ([***])
      with a balance in the amount of $[***] and dated August 31, 1999 ([***])
      in the amount of $[***] for activities in connection with [***]
      resolution. MERCK hereby agrees to pay those invoices on a non-precedent
      basis, making no admission that payment for activities covered by those
      invoices is required under the MANUFACTURING AGREEMENT. Payment of those
      invoices shall be made within five (5) business days of the execution date
      of this Amendment No. 3. MERCK's decision to make the payment is based
      solely on its desire to facilitate future relations between the parties.
      REGENRON hereby releases and forever waives any claim that it has or may
      have against MERCK for any and all work and activities covered by those
      invoices.

7.    The parties have engaged in ongoing discussions concerning various issues
      raised by REGENERON. To resolve those discussions, MERCK hereby agrees to
      make the following payments to REGENERON: (a) MERCK will pay REGENERON the
      amount of $[***] within five (5) business days of the execution date of
      this Amendment No. 3 and (b) MERCK will pay REGENERON the amount of $[***]
      on May 1, 2000 and $[***] on each November 1 and May 1 of the second
      through sixth CONTRACT YEARS. However, the payment of $[***] shall only be
      made on such specified dates if the MANUFACTURING AGREEMENT remains in
      effect on the date in question, as MERCK's obligation to make any such
      payment ceases with the Termination of the MANUFACTURING AGREEMENT.

      MERCK's decision to make the payments described in this Paragraph 7 is
      based solely on its desire to facilitate future Relations between the
      parties and is not an admission that any

                                       3
<PAGE>

      such payments are required under the MANUFACTURING AGREEMENT and does not
      establish any precedent to that effect. In consideration of the payments
      and compromises set forth herein and with the intent of facilitating
      future relations between the parties, the sufficiency of which both
      parties acknowledge, MERCK and REGENERON hereby release and forever waive
      any claim each has or may have against the other for increases or
      decreases in (a) FACILITY FEE, (b) BATCH FEES or (c) any other
      compensation required under the MANUFACTURING AGREEMENT, except as is
      expressly set forth within the specific terms of the MANUFACTURING
      AGREEMENT, as amended, or as may otherwise be agreed to in writing by the
      parties.

8.    Sections 1.9, 1.18 and 1.22 of the MANUFACTURING AGREEMENT shall be
      amended by replacing the reference in each to "Schedule A" with "Schedule
      A-1". Schedule A-1 is attached hereto and shall be incorporated into the
      MANUFACTURING AGREEMENT. However, Schedule A shall remain part of the
      MANUFACTURING AGREEMENT for the comparative purposes described below.
      MERCK understands that Schedule A-1 reflects a different and lesser space
      configuration then does Schedule A. However, should the amount and type of
      space identified in Schedule A as [***] and [***] become necessary to
      MANUFACTURE INTERMEDIATE and store SUBSTANCE, MATERIAL, SUPPLIES and
      INTERMEDIATE, then REGENERON shall make such amount and type of space
      available for MERCK, as the change from Schedule A to Schedule A-1 does
      not in any way change or otherwise relieve REGENERON of its obligation to
      MERCK under Section 4.2 of the MANUFACTURING AGREEMENT.

9.    Capitalized terms used in this Amendment No. 3 but not defined herein
      shall have the meanings as set forth in the MANUFACTURING AGREEMENT. Also,
      for clarity, paragraph 6 herein shall be subject to Sections 3, 24 and 25
      of the MANUFACTURING AGREEMENT, paragraph 8 shall be subject to Section
      4.2 of the MANUFACTURING AGREEMENT and Paragraphs 7 and 8 herein shall be
      subject to Sections 3, 21, 22, 24, 25, 28, 29 and 32 of the MANUFACTURING
      AGREEMENT.

10.   This Amendment No. 3 constitutes the entire agreement among the parties on
      the subject matter hereof and supersedes all other prior agreements and
      understandings, both written or oral among the parties with respect to the
      subject matter of this Amendment No. 3. No modifications, changes,
      alterations or additions to this Amendment No. 3 shall be effective unless
      in writing, properly

                                       4
<PAGE>

      executed by authorized representatives of both parties and identified as
      an amendment to this Amendment No. 3.

11.   This Amendment No. 3 may be executed in one or more counterparts, each of
      which shall for all purposes be deemed an original and all of which shall
      constitute one and the same Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 3 as of
the 9th of December 1999.

MERCK & CO., INC.                          REGENERON PHARMACEUTICALS, INC.

By:  /s/Bernard J. Kelley                  By:  /s/Murray A. Goldberg
     --------------------                       ---------------------

Title:  President, MMD                     Title:  Vice President

                                       5
<PAGE>

                                  SCHEDULE A-1

                                     [*****]

                                       6
<PAGE>

                                   SCHEDULE X

                                     [*****]

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]